Primary genetic disorders affecting high density lipoprotein (HDL).

Autor: Kosmas CE; Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, NY, USA., Silverio D; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Sourlas A; School of Medicine, University of Crete, Heraklion, Greece., Garcia F; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Montan PD; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Guzman E; Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Jazyk: angličtina
Zdroj: Drugs in context [Drugs Context] 2018 Sep 11; Vol. 7, pp. 212546. Date of Electronic Publication: 2018 Sep 11 (Print Publication: 2018).
DOI: 10.7573/dic.212546
Abstrakt: There is extensive evidence demonstrating that there is a clear inverse correlation between plasma high density lipoprotein cholesterol (HDL-C) concentration and cardiovascular disease (CVD). On the other hand, there is also extensive evidence that HDL functionality plays a very important role in atheroprotection. Thus, genetic disorders altering certain enzymes, lipid transfer proteins, or specific receptors crucial for the metabolism and adequate function of HDL, may positively or negatively affect the HDL-C levels and/or HDL functionality and subsequently either provide protection or predispose to atherosclerotic disease. This review aims to describe certain genetic disorders associated with either low or high plasma HDL-C and discuss their clinical features, associated risk for cardiovascular events, and treatment options.
Competing Interests: Disclosure and potential conflicts of interest: Constantine E Kosmas and Eliscer Guzman are members of the Dyslipidemia Speaker Bureau of Amgen, Inc. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2018/09/dic.212546-COI.pdf
Databáze: MEDLINE